Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET

Company Participants

Lee Roth - Burns McClellan, Investor Relations Advisors, Altimmune
Vipin Garg - Chief Executive Officer
Scott Harris - Chief Medical Officer
Andrew Shutterly - Acting Chief Financial Officer
Ray Jordt - Chief Business Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler
Liisa Bayko - Evercore
William Wood - B. Riley Securities

Operator

Good day, ladies and gentlemen, and welcome to Altimmune, Inc. Third Quarter 2024 Financial Results Conference Call. At this time all participants’ are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference call, Lee Roth of Burns McClellan, Investor Relations Advisors to Altimmune. Lee, you may begin.

Lee Roth

Thanks, operator. Good morning, everyone. And once again thank you for participating on the Altimmune’s third quarter 2024 financial results and business update conference call.

On today’s call you will hear from Dr. Vipin Garg, our Chief Executive Officer; Dr. Scott Harris, our Chief Medical Officer; and Andrew Shutterly, our acting Chief Financial Officer; and Dr. Scot Roberts, our Chief Scientific Officer and Greg Weaver, our newly appointed Chief Financial Officer are on the line as well and will join us for the Q&A session.

A press release covering our third quarter of 2024 financial results and corporate update was issued earlier this morning and can be found on the investor relations section of the company's website.

Before we begin, I'd like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those indicated. For a full review of the risk factors that could affect the company's future results and operations, we refer you to our filings with the SEC.

I'll also direct you to read the forward-looking statements disclaimer in our press release issued this morning, which is now available on our website. Any statements made on this call speak only as of today's date, November 12, 2024, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today. As a reminder, this call is being recorded and will be available for audio replay on the Altimmune website.